Author:
Perumal Jai,Balabanov Roumen,Balcer Laura,Galetta Steven,Sun Zhaonan,Li Hanyue,Rutledge Danette,Avila Robin L.,Fox Robert J.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Reference25 articles.
1. Cree BAC, Pradhan A, Pei J, Williams MJ, OPERA I and OPERA II clinical investigators. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the phase III OPERA I and OPERA II studies. Mult Scler Relat Disord. 2021;52:103010.
2. Cree BA, Stuart WH, Tornatore CS, Jeffery DR, Pace AL, Cha CH. Efficacy of natalizumab therapy in patients of African descent with relapsing multiple sclerosis: analysis of AFFIRM and SENTINEL data. Arch Neurol. 2011;68(4):464–8.
3. Herbert J, Rivera V, Ford C, et al. Effects of natalizumab on relapses and MRI outcomes in Hispanic patients with relapsing MS. 25th Congress of the European Committee of Treatment and Research in Multiple Sclerosis; 2009.
4. Onuorah HM, Charron O, Meltzer E, et al. Enrollment of non-white participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: a systematic review. Neurology. 2022;98(9):e880–92.
5. Williams MJ, Amezcua L, Okai A, et al. Real-world safety and effectiveness of dimethyl fumarate in black or African American patients with multiple sclerosis: 3-year results from ESTEEM. Neurol Ther. 2020;9(2):483–93.